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Introduction and Background: IL-17 pathway is being clinically 
targeted in immune-mediated diseases, most of which are associated 
with a significant cardiovascular risk. We investigated the relation-
ship between serum levels of IL-17 and the risk of cardiovascular 
events in patients with acute myocardial infarction.
Patients (or Materials) and Methods: We used data from patients 
enrolled in the prospective, multicenter French registry of acute 
ST elevation or non–ST-elevation myocardial Infarction (Fast-MI, 
NCT00673036). Of the 374 centers in France that treated patients 
with acute MI, 223 (60%) participated in the registry. Among these, 
100 centers recruited 1029 patients who contributed to a serum bank. 
Their baseline characteristics were comparable to the overall popu-
lation of the registry. Written informed consent was provided by 
each patient. More than 99% of patients were Caucasian. Two-year 
follow-up was > 98% complete.
Results: Serum levels of IL-17 were associated with the risk of all-
cause death and recurrent MI at 2 years, with levels of IL-17 below 
the median indicative of a worse outcome. The impact of IL-17 
remained significant after adjustment for known cardiovascular risk 
factors, CRP, and treatments including statins: hazard ratio (HR) = 
1.40 (1.03–1.91); P = 0.03.IL-17 inhibited mononuclear cell adhe-
sion to endothelium and reduced endothelial VCAM-1 expression. 
Patients with low (below the median) IL-17 levels and high (above 
the median) soluble VCAM-1 (sVCAM-1) levels were at particularly 
increased risk of death and MI: adjusted HR = 2.22 (1.32–3.75) 
compared with the high IL-17/low sVCAM-1 group (P = 0.002).
Conclusion: Low serum levels of IL-17 are associated with a higher risk 
of major cardiovascular events in Caucasian patients with acute MI. 
Our results raise possible concern about the use of inhibitors of IL-17 
pathway in clinical settings associated with a high cardiovascular risk.
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Introduction: Investigations based on quantitative sensory testing 
have consistently evidenced allodynia in FMS patients involving both 
spinal and supraspinal pain regulatory systems. Functional imaging 
studies have demonstrated enhanced neural activities in pain related 
brain areas as well as impairment of pain inhibition in the descending 
nociceptive regulatory system. Higher state of excitability of spinal 
nociceptive neurons as evidenced by lowered nociceptive flexion 
reflex R-III (NFR) threshold was reported for FMS patients. The NFR 
procedure has been shown to be a valuable tool to evaluate pharma-
cologically active therapeutic agents at the spinal level. Serotonin-
noradrenaline reuptake inhibitors have been shown to reduce pain 
in fibromyalgia syndrome patients possibly through descending 
monoaminergic pain pathways modulation. This randomized dou-
ble- blind, placebo-controlled trial assessed the pharmacodynamic 
activity of the dual-reuptake inhibitor milnacipran (MLN) at the 
spinal level by means of the objective spinal NFR.
Patients (or Materials) and Methods: Seven-week exposure (100, 
150, 200 mg/d) in female fibromyalgia patients. Evaluation consisted 
of extensive quantitative sensory testing, including determination of 
the nociceptive flexion reflex threshold (NFR), self-reported standard 
questionnaires investigating pain: visual analog scales; fibromyal-
gia impact, health-related quality of life, depression, and anxiety 
questionnaires as well as and Patient’s Global Impression of Change 
(PGIC). Analysis of covariance adjusted for baseline value was used 
for all end points.
Results: Seventy-seven (39 placebo, 38 milnacipran all doses) of 80 
randomized patients were available for analysis. The absence of influ-
ence of MLN (any dose) on the NFR surprisingly contrasted with the 
dose-dependent analgesic effect observed in MLN-treated patients 
with an adjusted change difference of –18.4 mm (–30.9; –5.8) in 
pain reduction between placebo and the maximum dosage (200 mg) 
MLN groups (P = 0.02). Unchanged depression and anxiety scores 
confirmed the predominant selectivity of the analgesic effect of MLN 
on nociceptive pain pathway. Self-reported questionnaires consist-
ently reflected the positive effects of MLN on quality of life and psy-
chological well-being. Odds ratio 5.1 for PGIC responders (ie, much/
very much improved) was significantly in favor of MLN (P = 0.04).
Conclusion: Milnacipran has a predominantly supraspinal analgesic 
effect as evidenced by the significant clinical benefits and the absence 
of changes in the nociceptive spinal reflex threshold. Higher dose 
was associated with higher pain reduction. Reported analgesia was 
independent of patients’ emotional status.
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